Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial

This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.

Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Michael B. Atkins, MD Tags: Conferences/ASCO Renal Cell Carcinoma News Videos Genitourinary Cancers Source Type: news